🔗 Share this article US and UK Agree to No-Tariff Pact on Drugs. Stock image of pharmaceutical exports. The UK and US have established a major bilateral deal that will keep zero import taxes on British medicine products entering the US market. Agreement Details of the Deal As part of the deal, the UK has committed to boost funding on drugs through the public health system. This move secures that import taxes on these crucial products will be held at nothing for a period of 36 months. This agreement comes after previous statements to hike import taxes on patented pharmaceutical products, with figures discussed reaching double the cost. "This arrangement between the United Kingdom bolsters the international landscape for cutting-edge drugs and establishes much-needed fairness to transatlantic medicine commerce," a statement declared. Commercial Impact Medicines constitute one of the the United Kingdom's biggest exports to the US, which is easily the largest market for leading British pharmaceutical firms. Export figures show that in the 12 months to the end of last September, the UK shipped medicines worth billions to the US. This value accounted for 17.4% of all goods exports in that period. "This guarantee protects employment, increases funding and paves the way for the UK to become a international leader for biotech and pharma," a government official stated. Specific NHS Changes The deal entails several key pledges from the UK: Price Threshold Increase: The UK will raise the cost ceiling at which it considers new treatments to be too expensive by 25%. Increased NHS Spending: There is a goal to increase total public funding on medicines from 0.3% of GDP to 0.6 percent over the next decade. Rebate Cap: The percentage drug companies must refund to the NHS to prevent overspending will be restricted at fifteen percent. Last year, repayments topped twenty percent. Recent Tensions The deal comes amid a ongoing dispute between the drug companies and the British authorities over medicine costs and approval rates. The disagreement were heightened by arguments that American consumers were paying several times more for the equivalent treatments than people in the Britain and the EU. Recently, several large drug company projects in the UK have been delayed or scrapped, while major funding commitments have been announced toward projects in the United States. A senior figure publicly accepted that the NHS needed to increase expenditure on treatments, noting that its expenditure on drugs had decreased as a share of its total funding over the previous ten-year period.
Stock image of pharmaceutical exports. The UK and US have established a major bilateral deal that will keep zero import taxes on British medicine products entering the US market. Agreement Details of the Deal As part of the deal, the UK has committed to boost funding on drugs through the public health system. This move secures that import taxes on these crucial products will be held at nothing for a period of 36 months. This agreement comes after previous statements to hike import taxes on patented pharmaceutical products, with figures discussed reaching double the cost. "This arrangement between the United Kingdom bolsters the international landscape for cutting-edge drugs and establishes much-needed fairness to transatlantic medicine commerce," a statement declared. Commercial Impact Medicines constitute one of the the United Kingdom's biggest exports to the US, which is easily the largest market for leading British pharmaceutical firms. Export figures show that in the 12 months to the end of last September, the UK shipped medicines worth billions to the US. This value accounted for 17.4% of all goods exports in that period. "This guarantee protects employment, increases funding and paves the way for the UK to become a international leader for biotech and pharma," a government official stated. Specific NHS Changes The deal entails several key pledges from the UK: Price Threshold Increase: The UK will raise the cost ceiling at which it considers new treatments to be too expensive by 25%. Increased NHS Spending: There is a goal to increase total public funding on medicines from 0.3% of GDP to 0.6 percent over the next decade. Rebate Cap: The percentage drug companies must refund to the NHS to prevent overspending will be restricted at fifteen percent. Last year, repayments topped twenty percent. Recent Tensions The deal comes amid a ongoing dispute between the drug companies and the British authorities over medicine costs and approval rates. The disagreement were heightened by arguments that American consumers were paying several times more for the equivalent treatments than people in the Britain and the EU. Recently, several large drug company projects in the UK have been delayed or scrapped, while major funding commitments have been announced toward projects in the United States. A senior figure publicly accepted that the NHS needed to increase expenditure on treatments, noting that its expenditure on drugs had decreased as a share of its total funding over the previous ten-year period.